Health Technology Assessment (HTA) is the systematic assessment of the comparative effectiveness and cost of health technologies and services and can provide the economic and clinical evidence needed for decisions about what products to purchase or services to offer to achieve value for money. Operationalizing HTA as a routine component of procurement and provider payment decisions is a priority in many LMICs with emerging National Health Insurance Funds and a consideration amongst global funding conduits, such as the Global Fund and Gavi, as they target resources to promote sustainable systems . Bilateral donors such as DFID have also signalled their commitment to maximizing the value for money of their investments. CGD's work helps inform how HTA can be applied to different settings and what the informational and institutional resource requirements for such applications may be.
Support More Work Like This.
Your contribution makes it possible for the Center’s researchers to devise practical, evidence-based solutions for today’s most pressing development challenges.